Latest Biotech News

A BMC Medicine study reports that intranasally delivered recombinant BMP2/6 proteins slowed dopaminergic neuron degeneration in mouse models of Parkinsonian pathology while improving motor...

A multicenter study of 167 lung cancer patients found that persistent emotional distress spanning neoadjuvant therapy through surgery independently tracks with worse overall survival and...

A study identifies the endogenous VEGF-A splice variant VEGF165b as an endogenous shield against inflammatory vascular leak in acute lung injury and acute respiratory distress syndrome. By...

Research in Nature shows gamma delta T cells use adaptive T cell receptors in real time to drive rapid, innate-like tissue surveillance and anti-tumor responses. The study challenges the textbook...

A preclinical rat study reports that GalNAc-targeted siRNA silencing of hepatic complement C3 nearly eliminated plasma complement and preserved acetylcholine receptors while reducing muscle...

The NIH has funded a $4 million study to investigate why weight returns after stopping GLP-1 receptor agonist medications, with investigators at UTHealth Houston leading the work. The research...

A two-sequence shortened liver MRI protocol using hepatobiliary phase imaging detected tumor recurrence after microwave ablation with reported 87.5% sensitivity and 97.6% specificity. The study...

European neonatal specialists published the first ESPR recommendation for a Vascular Access Management Plan (VAMP), aiming to standardize device choice and reduce complications in newborns. The...

FDA chief scientist Steven Kozlowski said the agency plans to expand its Focus Areas of Regulatory Science (FARS) update to include aging and longevity medicine, aiming to define shared,...

Immix Biopharma announced a $125 million public offering shortly after interim Phase II NEXICART-2 results showed its BCMA-targeted CAR-T, NXC-201, delivered an 89% complete response rate among 45...

The FDA said it plans to expand the agency’s Focus Areas of Regulatory Science (FARS) to include aging and longevity, signaling a formal push to standardize how interventions in “healthspan” are...

Two late-stage oncology signals highlighted breast cancer development and treatment strategy refinement. A phase 3 evERA trial in the New England Journal of Medicine reported that adding...

The FDA opened a new clinical trial modernization office within the Center for Drug Evaluation and Research (CDER) as part of a broader push to speed up trial execution. The agency framed the...

Circle secured a $92.5 million funding round to push its cyclin D1 program ahead of its clinical lead, with preclinical combination data driving the funding priority. The company positioned...

Aviceda Therapeutics is winding down after a Phase 2 setback for its geographic atrophy program, according to a source familiar with the decision. The company had planned to advance an eye drug...

New research coverage points to a broader immunotherapy shift away from a single “killer T-cell” framing toward more nuanced effector biology. One report described complement footprints being...

Two phase III trials published in December 2025—BRUIN CLL-313 and BRUIN CLL-314—delivered clinically consequential results for chronic lymphocytic leukemia, with pirtobrutinib positioned as a...

A landmark clinical trial reported that a breath test can spot lung cancer with over 90% accuracy, addressing a core bottleneck in cancer control: late diagnosis. The coverage highlighted that...

A new study reported that nanoparticle paclitaxel can improve tumor control when added to liver-directed chemoembolization for breast cancer metastases. The approach targets the major clinical...

New signals in cell therapy and manufacturing emphasize how developers are refining both targeting and production constraints. Coverage described lipid nanoparticle CAR engineering that highlights...